中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

高血压与非酒精性脂肪性肝病的关系

王欣 胡义扬 刘平 冯琴

引用本文:
Citation:

高血压与非酒精性脂肪性肝病的关系

DOI: 10.3969/j.issn.1001-5256.2020.11.042
基金项目: 

国家自然基金重点项目(81830119); 国家科技重大专项“重大新药创制”项目(2019ZX09201001-001-002); 

详细信息
  • 中图分类号: R575.5;R544.1

Association between hypertension and nonalcoholic fatty liver disease

Research funding: 

 

  • 摘要:

    非酒精性脂肪性肝病(NAFLD)与高血压同为代谢综合征的重要组成部分,二者之间有很强的关联性。通过临床数据分析了NAFLD与高血压之间的联系。简述了二者之间相互影响的共同可能机制。其中,胰岛素抵抗、肠道菌群、肾素-血管紧张素-醛固酮系统在二者的发病机制中起着重要的作用。同时也总结了肾素-血管紧张素-醛固酮系统抑制药以及利尿剂在NAFLD治疗中的应用,为今后进一步明确二者之间的关系,深入了解二者相互影响的机制以及NAFLD合并高血压的治疗提供参考。

     

  • [1]ZHOU J,ZHOU F,WANG W,et al.Epidemiological feature of NAFLD from 1999 to 2018 in China[J].Hepatology,2020,75(5):1851-1864.
    [2]ZHOU F,ZHOU J,WANG W,et al.Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and meta-analysis[J].Hepatology,2019,70(4):1119-1133.
    [3]LONARDO A,NASCIMBENI F,MANTOVANI A,et al.Hypertension,diabetes,atherosclerosis and NASH:Cause or consequence?[J].J Hepatol,2018,68(2):335-352.
    [4]MILLS KT,STEFANESCU A,HE J.The global epidemiology of hypertension[J].Nat Rev Nephrol,2020,16(4):223-237.
    [5]LOPEZ-SUAREZ A,GUERRERO JM,ELVIRA-GONZALEZ J,et al.Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase[J].Eur J Gastroenterol Hepatol,2011,23(11):1011-1017.
    [6]LORBEER R,BAYERL C,AUWETER S,et al.Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease[J].J Hypertens,2017,35(4):737-744.
    [7]ANENT EC,ONI ET,MARTIN SS,et al.Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of card iometabolic risk[J].J Hypertens,2015,33(6):1207-1214.
    [8]FENG RN,DU SS,WANG C,et al.Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population[J].World J Gastroenterol,2014,20(47):17932-17940.
    [9]BONNET F,GASTALDELLI A,PIHAN-LE BARS F,et al.Gamma-glutamyltransferase,fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies[J].J Hypertens,2017,35(3):493-500.
    [10]HUH JH,AHN SV,KOH SB,et al.A prospective study of fatty liver index and incident hypertension:The KoGESARIRANG study[J].PLoS One,2015,10(11):e0143560.
    [11]RYOO JH,SUH YJ,SHIN HC,et al.Clinical association between non-alcoholic fatty liver disease and the development of hypertension[J].J Gastroenterol Hepatol,2014,29(11):1926-1931.
    [12]SUNG KC,WILD SH,BYRNE CD.Development of new fattyliver,or resolution of existing fatty liver,over five years of follow-up,and risk of incident hypertension[J].J Hepatol,2014,60(5):1040-1045.
    [13]QIAN LY,TU JF,DING YH,et al.Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population:Normal is not the new normal[J].Medicine(Baltimore),2016,95(29):e4293.
    [14]WANG Y,ZENG Y,LIN C,et al.Hypertension and non-alcoholic fatty liver disease proven by transient elastography[J].Hepatol Res,2016,46(13):1304-1310.
    [15]MA J,HWANG SJ,PEDLEY A,et al.Bi-directional analysis between fatty liver and cardiovascular disease risk factors[J].J Hepatol,2017,66(2):390-397.
    [16]SORRENTINO P,TERRACCIANO L,D'ANGELO S,et al.Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin,HOMA-IR,and hypertension[J].Am J Gastroenterol,2010,105(2):336-344.
    [17] SINGH S,ALLEN AM,WANG Z,et al.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:A systematic review and meta-analysis of paired-biopsy studies[J].Clin Gastroenterol Hepatol,2015,13(4):643-654.
    [18] European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol,2016,64(6):1388-1402.
    [19]NAKAMURA M,YAMAZAKI O,SHIRAI A,et al.Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome[J].Kidney Int,2015,87(3):535-542.
    [20]ALAM S,MUSTAFA G,ALAM M,et al.Insulin resistance in development and progression of nonalcoholic fatty liver disease[J].World J Gastrointest Pathophysiol,2016,7(2):211-217.
    [21]KHAN RS,BRIL F,CUSI K,et al.Modulation of insulin resistance in nonalcoholic fatty liver disease[J].Hepatology,2019,70(2):711-724.
    [22]BOLLER S,JOBLIN BA,XU L,et al.From signal transduction to signal interpretation:An alternative model for the molecular function of insulin receptor substrates[J].Arch Physiol Biochem,2012,118(3):148-155.
    [23]GUO S.Insulin signaling,resistance,and the metabolic syndrome:Insights from mouse models into disease mechanisms[J].J Endocrinol,2014,220(2):T1-T23.
    [24]HORITA S,SEKI G,YAMADA H,et al.Insulin resistance,obesity,hypertension,and renal sodium transport[J].Int J Hypertens,2011,2011:391762.
    [25]ARTUNC F,SCHLEICHER E,WEIGERT C,et al.The impact of insulin resistance on the kidney and vasculature[J].Nat Rev Nephrol,2016,12(12):721-737.
    [26]MINEMURA M,SHIMIZU Y.Gut microbiota and liver diseases[J].World J Gastroenterol,2015,21(6):1691-1702.
    [27]JI Y,YIN Y,LI Z,et al.Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease(NAFLD)[J].Nutrients,2019,11(8):1712.
    [28]MARQUES FZ,MACKAY CR,KAYE DM.Beyond gut feelings:How the gut microbiota regulates blood pressure[J].Nat Rev Cardiol,2018,15(1):20-32.
    [29]LEUNG C,RIVERA L,FURNESS JB,et al.The role of the gutmicrobiota in NAFLD[J].Nat Rev Gastroenterol Hepatol,2016,13(7):412-425.
    [30]KANG Y,CAI Y.Gut microbiota and hypertension:From pathogenesis to new therapeutic strategies[J].Clin Res Hepatol Gastroenterol,2018,42(2):110-117.
    [31]TE RIET L,van ESCH JH,ROKS AJ,et al.Hypertension:Renin-angiotensin-aldosterone system alterations[J].Circ Res,2015,116(6):960-975.
    [32]PASCHOS P,TZIOMALOS K.Nonalcoholic fatty liver disease and the renin-angiotensin system:Implications for treatment[J].World J Hepatol,2012,4(12):327-331.
    [33]MATTHEW MORRIS E,FLETCHER JA,THYFAULT JP,et al.The role of angiotensin II in nonalcoholic steatohepatitis[J].Mol Cell Endocrinol,2013,378(1-2):29-40.
    [34]WU Y,MA KL,ZHANG Y,et al.Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease[J].Liver Int,2016,36(10):1525-1534.
    [35]TOBLLI JE,MUNOZ MC,CAO G,et al.ACE inhibition and AT1receptor blockade prevent fatty liver and fibrosis in obese Zucker rats[J].Obesity(Silver Spring),2008,16(4):770-776.
    [36]POLYZOS SA,KOUNTOURAS J,MANTZOROS CS,et al.Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance,non-invasive indices of steatosis and fibrosis,and adipokine levels in non-alcoholic fatty liver disease:A randomized controlled trial[J].Diabetes Obes Metab,2017,19(12):1805-1809.
    [37]YOKOHAMA S,YONEDA M,HANEDA M,et al.Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis[J].Hepatology,2004,40(5):1222-1225.
    [38]GEORGESCU EF,IONESCU R,NICULESCU M,et al.Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis[J].World J Gastroenterol,2009,15(8):942-954.
    [39]MILIC S,MIKOLASEVIC I,KRZNARIC-ZRNIC I,et al.Nonalcoholic steatohepatitis:emerging targeted therapies to optimize treatment options[J].Drug Des Devel Ther,2015,9:4835-4845.
    [40]MCPHERSON S,WILKINSON N,TINIAKOS D,et al.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis[J].PLoS One,2017,12(4):e0175717.
  • 加载中
计量
  • 文章访问数:  497
  • HTML全文浏览量:  29
  • PDF下载量:  131
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-28
  • 出版日期:  2020-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回